The specific objectives of this IOF project are: (1) further development of results in support of patent applications, (2) further validation of the use of bacterial extracellular vesicles (BEV) as a diagnostic marker for permeability and dysbiosis of the intestine in a larger cohort of HIV patients and cancer patients treated with radiotherapy, chemotherapy or immunotherapy, (3) bioinformatics analysis of the microbial dysbiosis data and of the recently obtained proteome data whereby new biomarkers linked to BEVs can be obtained: new IP can be filed , (4) market analysis, identification of industrial partners who are interested in a further R&D type collaboration with the ultimate goal of licensing the technology.